Home High-Flow Nasal Cannula vs. Noninvasive Ventilation for Stable Chronic Respiratory Failure
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age40+
SponsorWonju Severance Christian Hospital
About this trial
The goal of this clinical trial is to compare the effects of home high-flow nasal cannula (HFNC) therapy and noninvasive ventilation (NIV) in patients with stable chronic hypercapnic respiratory failure. The main questions it aims to answer are:
* Does HFNC or NIV reduce blood carbon dioxide levels more effectively? * How well do patients tolerate and adhere to each therapy? * Are there differences in oxygen saturation, respiratory rate, and quality of life between the two treatments?
Participants Will:
* Use either HFNC (myAirvo2®) or NIV (Trilogy Evo®) every night for at least 4 hours over a 6-week period. * Visit the hospital for checkups and arterial blood gas tests at the end of each 6-week period. * Switch to the alternate device after six weeks as part of the crossover study design. * Have their device usage recorded and analyzed.
Eligibility criteria
Qualifiers
Adult aged 40 years or older
Diagnosed with COPD
Arterial blood gas test, pCO2 > 45 mmHg at stable status
A person who can read or write in Korean
Disqualifiers
A person who disagrees with the content of a informed consent
Those who have difficulty wearing NIV or HFNC
Cognitive impairment or apsychiatric disorder
Hypoxic or hypercapnic exacerbation within the previous four weeks
Trial design
Treatments tested in this trial
- High-Flow Nasal Cannula
- Noninvasive Ventilation
Treatment groups
38 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov